JP2001502299A - リポソーム - Google Patents

リポソーム

Info

Publication number
JP2001502299A
JP2001502299A JP10513398A JP51339898A JP2001502299A JP 2001502299 A JP2001502299 A JP 2001502299A JP 10513398 A JP10513398 A JP 10513398A JP 51339898 A JP51339898 A JP 51339898A JP 2001502299 A JP2001502299 A JP 2001502299A
Authority
JP
Japan
Prior art keywords
liposome
polynucleotide
liposomes
dna
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10513398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001502299A5 (enExample
Inventor
グレゴリー グレゴリアディス
Original Assignee
リポゼン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619172.1A external-priority patent/GB9619172D0/en
Priority claimed from GBGB9625917.1A external-priority patent/GB9625917D0/en
Priority claimed from GBGB9713994.3A external-priority patent/GB9713994D0/en
Application filed by リポゼン リミテッド filed Critical リポゼン リミテッド
Publication of JP2001502299A publication Critical patent/JP2001502299A/ja
Publication of JP2001502299A5 publication Critical patent/JP2001502299A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP10513398A 1996-09-13 1997-09-15 リポソーム Ceased JP2001502299A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9619172.1 1996-09-13
GBGB9619172.1A GB9619172D0 (en) 1996-09-13 1996-09-13 Liposomes
GB9625917.1 1996-12-13
GBGB9625917.1A GB9625917D0 (en) 1996-12-13 1996-12-13 Liposomes
GBGB9713994.3A GB9713994D0 (en) 1997-07-01 1997-07-01 Liposomes
GB9713994.3 1997-07-01
PCT/GB1997/002490 WO1998010748A1 (en) 1996-09-13 1997-09-15 Liposomes

Publications (2)

Publication Number Publication Date
JP2001502299A true JP2001502299A (ja) 2001-02-20
JP2001502299A5 JP2001502299A5 (enExample) 2005-09-08

Family

ID=27268476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10513398A Ceased JP2001502299A (ja) 1996-09-13 1997-09-15 リポソーム

Country Status (11)

Country Link
US (1) US7790696B2 (enExample)
EP (2) EP0938298B1 (enExample)
JP (1) JP2001502299A (enExample)
KR (1) KR100507660B1 (enExample)
CN (1) CN1138533C (enExample)
AT (2) ATE395904T1 (enExample)
AU (1) AU728581B2 (enExample)
CA (1) CA2271388C (enExample)
DE (2) DE69717661T2 (enExample)
ES (2) ES2305157T3 (enExample)
WO (1) WO1998010748A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525898A (ja) * 2001-02-21 2004-08-26 ノヴォソム アクチェンゲゼルシャフト 両性リポソーム及びその使用
JP2005245342A (ja) * 2004-03-05 2005-09-15 Mitsubishi Kagaku Bio-Clinical Laboratories Inc 細胞中ａｔｐの定量法
JP2012532200A (ja) * 2009-07-06 2012-12-13 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
JP2015520195A (ja) * 2012-06-08 2015-07-16 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 非肺標的細胞へのｍＲＮＡの経肺送達
JP2023550667A (ja) * 2020-04-10 2023-12-05 エランコ・アニマル・ヘルス・ゲーエムベーハー 免疫刺激性組成物

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361459A1 (en) * 1999-02-05 2000-08-10 Salam Abdul Kadhim Use of cationic lipids to generate anti-tumor immunity
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
WO2001024773A1 (en) * 1999-10-01 2001-04-12 Lipoxen Technologies Limited Liposome-entrapped dna oral vaccines
EP1237541B1 (en) 1999-12-13 2004-09-01 Lipoxen Technologies Limited Liposomes comprising a complex of a polyanionic compound and calcium phosphate
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
JP4294584B2 (ja) 2002-07-05 2009-07-15 リポクセン・テクノロジーズ・リミテツド 核酸ワクチン接種の免疫応答を高めるための方法
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CN100400667C (zh) * 2006-06-27 2008-07-09 浙江大学 脂质体包裹弓形虫pGRA4真核表达质粒的方法及用途
CA2687208C (en) 2006-12-22 2017-02-14 Soluciones Biotecnologicas Innovacion Ltda Process and formulation for immunizing fish in aquaculture systems
RU2367443C1 (ru) * 2008-02-28 2009-09-20 Общество с ограниченной ответственностью "Битеп" Средство на основе природных фосфолипидов
EP2184054A1 (en) 2008-11-08 2010-05-12 Lipoxen Technologies Limited Small Interfering RNA Delivery
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
KR101773643B1 (ko) * 2010-04-28 2017-08-31 교와 핫꼬 기린 가부시키가이샤 양이온성 지질
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
RU2491062C2 (ru) * 2011-03-16 2013-08-27 Общество С Ограниченной Ответственностью "Биотехнологии Пущино" Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
MX2016008568A (es) * 2013-12-27 2017-04-13 Teloregen Inc Composiciones y metodos para proveer telomerasa activa a las celulas in vivo.
AU2015206016B2 (en) * 2014-01-17 2020-07-23 Fundacio Institut Catala De Nanociencia I Nanotecnologia Liposome-based immunotherapy
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
US20220333178A1 (en) 2021-03-22 2022-10-20 Illumina Cambridge Limited Methods for improving nucleic acid cluster clonality

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6447381A (en) * 1987-08-19 1989-02-21 Vitamin Kenkyusho Kk Preparation of liposome containing sealed gene
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPH02135092A (ja) * 1988-11-14 1990-05-23 Bitamin Kenkyusho:Kk 細胞への遺伝子導入法
WO1991017424A1 (en) * 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JPH04108391A (ja) * 1990-08-27 1992-04-09 Vitamin Kenkyusho:Kk 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
WO1995004524A1 (en) * 1993-08-06 1995-02-16 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
WO1996026179A1 (en) * 1995-02-21 1996-08-29 Imarx Pharmaceutical Corp. Novel cationic lipids and the use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
EP0172007B1 (en) 1984-08-10 1991-05-22 Syntex (U.S.A.) Inc. Stable liposomes with aqueous-soluble medicaments and methods for their preparation
US5550289A (en) 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPH0662517B2 (ja) 1985-01-07 1994-08-17 シンテツクス（ユー・エス・エイ）インコーポレイテツド 置換アルキルートリ置換アンモニウム界面活性剤
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4882172A (en) * 1988-04-08 1989-11-21 Nabisco Brands, Inc. System for processing chewing gum
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DK0678017T3 (da) * 1993-11-05 1998-10-19 Amgen Inc Liposomfremstilling og materialeindkapslingsfremgangsmåde
HUT75162A (en) * 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
JP4335310B2 (ja) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPS6447381A (en) * 1987-08-19 1989-02-21 Vitamin Kenkyusho Kk Preparation of liposome containing sealed gene
JPH02135092A (ja) * 1988-11-14 1990-05-23 Bitamin Kenkyusho:Kk 細胞への遺伝子導入法
WO1991017424A1 (en) * 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JPH04108391A (ja) * 1990-08-27 1992-04-09 Vitamin Kenkyusho:Kk 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
WO1995004524A1 (en) * 1993-08-06 1995-02-16 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
WO1996026179A1 (en) * 1995-02-21 1996-08-29 Imarx Pharmaceutical Corp. Novel cationic lipids and the use thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525898A (ja) * 2001-02-21 2004-08-26 ノヴォソム アクチェンゲゼルシャフト 両性リポソーム及びその使用
JP2014218520A (ja) * 2001-02-21 2014-11-20 マリナ バイオテック インコーポレイテッド 両性リポソーム及びその使用
JP2016104786A (ja) * 2001-02-21 2016-06-09 マリナ バイオテック インコーポレイテッド 両性リポソーム及びその使用
JP2005245342A (ja) * 2004-03-05 2005-09-15 Mitsubishi Kagaku Bio-Clinical Laboratories Inc 細胞中ａｔｐの定量法
JP2012532200A (ja) * 2009-07-06 2012-12-13 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
JP2015520195A (ja) * 2012-06-08 2015-07-16 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 非肺標的細胞へのｍＲＮＡの経肺送達
JP2023550667A (ja) * 2020-04-10 2023-12-05 エランコ・アニマル・ヘルス・ゲーエムベーハー 免疫刺激性組成物

Also Published As

Publication number Publication date
DE69717661D1 (de) 2003-01-16
DE69738719D1 (de) 2008-07-03
CN1138533C (zh) 2004-02-18
KR100507660B1 (ko) 2005-08-10
ES2305157T3 (es) 2008-11-01
EP1254657B1 (en) 2008-05-21
CA2271388C (en) 2007-11-06
EP1254657A3 (en) 2003-03-05
US7790696B2 (en) 2010-09-07
CN1237102A (zh) 1999-12-01
EP0938298B1 (en) 2002-12-04
ATE395904T1 (de) 2008-06-15
WO1998010748A1 (en) 1998-03-19
AU728581B2 (en) 2001-01-11
ATE228824T1 (de) 2002-12-15
EP0938298A1 (en) 1999-09-01
KR20000036088A (ko) 2000-06-26
EP1254657A2 (en) 2002-11-06
CA2271388A1 (en) 1998-03-19
ES2187812T3 (es) 2003-06-16
US20080286353A1 (en) 2008-11-20
AU4215497A (en) 1998-04-02
DE69717661T2 (de) 2003-09-25

Similar Documents

Publication Publication Date Title
KR100507660B1 (ko) 리포좀
US7384923B2 (en) Liposomes
CN112384205B (zh) 信使rna疫苗及其用途
Smyth Templeton Cationic liposome-mediated gene delivery in vivo
JP4800485B2 (ja) ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法
Li et al. Nonviral gene therapy
US9737484B2 (en) Amphoteric liposomes
JP4951338B2 (ja) 脂質に封入された干渉ｒｎａ
JPH11512712A (ja) 生物学的に活性な物質を細胞に送達するためのエマルジョンおよびミセル処方物
JP2008518998A (ja) 活性物質としてオリゴヌクレオチドを含む医薬組成物におけるまたはそれに関する改善
JP2025160111A (ja) 抗原提示細胞を標的とする脂質組成物及びその使用
CN115920019A (zh) 一种治疗肺癌及其骨转移的mRNA疫苗及其制备方法与应用
CN120835876A (zh) 包括具有支化结构的电离脂质的脂质纳米粒制剂及其用途
US7008791B1 (en) Liposome-entrapped DNA oral vaccines
HK40127068A (en) Lipid nanoparticles
HK40041286B (en) Lipid nanoparticles
Sullivan Non-Viral Gene Therapy
HK40041286A (en) Lipid nanoparticles
HK1121382B (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
JPWO1997031656A1 (ja) 肝細胞への安定的な遺伝子導入のための組成物及び該組成物を用いた遺伝子導入方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041108

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20041108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100607

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20100816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100928